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We reviewed information from a US pharmacy beneﬁ  ts 
manager database from 2004 through 2005 during periods 
with little inﬂ  uenza activity. We calculated rates of oseltami-
vir prescriptions to enrollees. Prescription rates increased 
signiﬁ  cantly from 27.3/100,000 in 2004 to 134/100,000 in 
2005 (p<0.05), which suggested that personal stockpiling of 
oseltamivir occurred.
F
rom 2003 through 2006, avian inﬂ  uenza virus (H5N1) 
spread from Southeast Asia to Africa, Europe, and the 
Middle East (1), and media coverage about the risk for hu-
man infection and the potential for an inﬂ  uenza pandemic 
increased. Two classes of medications are available to treat 
inﬂ  uenza: neuraminidase inhibitors (NIs), which include 
oseltamivir and zanamivir, and adamantanes, which include 
amantadine and rimantadine (2). NIs are recommended by 
the World Health Organization for treatment of avian inﬂ  u-
enza virus (H5N1) infection because isolates have shown
adamantane resistance (3). During the fall of 2005, NIs 
were in limited supply (4).
In 2005, concern was expressed in the medical literature 
about possible personal stockpiling of NIs for use during an 
inﬂ  uenza pandemic (5). We undertook this study to look for 
evidence of oseltamivir stockpiling, to understand the mag-
nitude of the practice, and to discern who was receiving and 
prescribing these drugs. We collaborated with a pharmacy 
beneﬁ   ts management company to examine antiviral pre-
scriptions and oseltamivir prescription ﬁ  lling in the United 
States during calendar weeks 36–44 in 2004 and 2005. These 
weeks were chosen because they had little inﬂ  uenza activity 
in either year and because reports of oseltamivir stockpiling 
occurred during this period in 2005 (6–9).
The Study
We used a database from Medco Health Solutions, Inc. 
(Franklin Lakes, NJ, USA), a pharmacy beneﬁ  ts manage-
ment company serving >50 million US members. We exam-
ined ﬁ  lled prescriptions for oseltamivir by members from 
January 2002 through May 2006. Available member data 
included demographic information, medication dispensed, 
prescriber identiﬁ  cation, and pharmacy dispensing history. 
Member-level historic pharmacy dispensing data were used 
to assign members into chronic disease classiﬁ  cations (10). 
Prescribers were cross-referenced with an American Medi-
cal Association member database to determine specialty 
and years since medical school graduation. We were able to 
cross-reference 64% of prescribing physicians by specialty 
and years since medical school graduation. The Centers for 
Disease Control and Prevention (Atlanta, GA, USA) de-
termined that institutional review board approval was not 
needed for this study because we received aggregated data 
that was anonymous and not identiﬁ  ed.
To assess media coverage, we queried the LexisNexis 
US News database (www.lexisnexis.com) for total weekly 
news reports from August 1, 2003, through August 30, 
2006, referring to avian inﬂ  uenza and oseltamivir. Weekly 
virologic data from the World Health Organization and Na-
tional Respiratory and Enteric Virus Surveillance System 
collaborating laboratories were used to assess US inﬂ  uenza 
activity during 2004 and 2005 (6,7).
Oseltamivir prescription rates were calculated per 
100,000 enrolled members and per 1,000 prescribing phy-
sicians. Binomial distributions were used to estimate vari-
ances for rates. Relative rate ratios (RRs) and 95% conﬁ  -
dence intervals (CIs) were calculated for 2004 and 2005 
data. P values <0.05 were considered statistically signiﬁ  -
cant. Analyses were performed with SAS version 9.0 statis-
tical software (SAS Institute, Cary, NC, USA).
Weekly rates of ﬁ  lled prescriptions for oseltamivir and 
percentage of samples positive for inﬂ  uenza from October 
1, 2002, through June 1, 2006, were temporally associated 
before the 2005–06 inﬂ  uenza season (Figure 1). During the 
fall of 2005, prescriptions for oseltamivir increased without 
an associated increase in the percentage of samples testing 
positive for inﬂ  uenza. In contrast, during the same period 
there was a temporal relationship between weekly oselta-
mivir prescription rates and media reports of avian inﬂ  u-
enza and oseltamivir (Figure 1).
The proportion of oseltamivir prescriptions to total 
anti-inﬂ  uenza prescriptions increased from 37.0% in 2004 
to 76.9% in 2005 (Table 1). The 2005 oseltamivir prescrip-
tion rate of 133/100,000 during weeks 36–44 was ≈5× the 
2004 rate of 27.3/100,000 (RR 4.88, 95% CI 4.79–4.97) 
(Table 1).
DISPATCHES
1280  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 8, August 2008
1This study was presented, in part, at the Infectious Diseases 
Society of America annual meeting in Toronto, Ontario, Canada, 
October 14, 2006, and in poster form at the Options for the Control 
of Inﬂ  uenza Conference, Toronto, June 17, 2007.
2Current afﬁ  liation: University of Washington, Seattle, WA, USA.
*Centers for Disease Control and Prevention, Atlanta, GA, USA; and 
†Medco Health Solutions, Inc., Franklin Lakes, New Jersey, USA
DOI: 10.3201/eid1408.080074Oseltamivir Prescribing, USA, 2004–2005
Women were more likely to receive oseltamivir pre-
scriptions than men in 2004 (RR 1.19, 95% CI 1.16–1.24) 
and 2005 (RR 1.07, 95% CI 1.05–1.09). Prescription rates 
increased from 2004 to 2005 for all age groups (Table 2). 
The highest prescription rates in 2005 were for persons 50–
64 years of age (211/100,000) and those >65 years of age 
(168/100,000). Members <18 years of age had a >7-fold 
increase in prescription rates from 2004 to 2005.
Among adults, prescription rates were consistently 
higher in 2005 than in 2004, irrespective of chronic disease 
classiﬁ  cation (Table 2). In 2005, the highest oseltamivir 
prescription rate was 268.5/100,000 for enrollees with pul-
monary disease, and the lowest rate was 89.5/100,000 for 
those without chronic disease. The greatest rate increase 
from 2004 to 2005 occurred among those without chronic 
disease (RR 6.36, 95% CI 6.10–6.62). Among enrollees of 
all ages during weeks 36–44 in 2005, approximately one 
third of oseltamivir prescriptions were ﬁ  lled by members 
without chronic disease.
In 2004 and 2005, general internists had the highest 
average prescribing rate for oseltamivir (45.3/1,000 and 
191.1/1,000, respectively) (Figure 2). Pediatricians had the 
lowest rates in both years (2.9/1,000 and 32.7/1,000).
For all prescribers in 2004 and 2005, oseltamivir pre-
scription rates increased with years since the prescriber’s 
medical school graduation. The lowest prescription rate 
in 2005 (1.7/1,000) was observed in prescribers who 
graduated from medical school in the previous 5 years, 
followed by prescribers with 5–10 years (4.9/1,000) and 
11–19 years (6.6/1,000) since graduation. The highest rate 
(10.4/1,000) was observed in prescribers with >20 years 
since graduation.
Conclusions
Rates of ﬁ  lled oseltamivir prescriptions during calen-
dar weeks 36–44 increased from 2004 to 2005. These weeks 
in 2005 were noteworthy for increased media references to 
oseltamivir and avian inﬂ  uenza, although there was little 
inﬂ  uenza activity. Low levels of inﬂ  uenza-like illness and 
respiratory syncytial virus activity also were documented 
during this period (6,11).
Among Medco enrollees, the highest prescription rates 
were for groups with the greatest risk for inﬂ  uenza-asso-
ciated complications: persons >50 years of age and adults 
with chronic diseases (2). However, oseltamivir prescrip-
tion rates increased from 2004 to 2005 for each age and 
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Figure 1. Weekly inﬂ   uenza activity, oseltamivir 
prescription rates for enrollees of all ages, and 
LexisNexis references to avian inﬂ  uenza  and 
oseltamivir, United States, 2003–2006. *World Health 
Organization and National Respiratory and Enteric 
Virus Surveillance System collaborating laboratories 
in the United States. †LexisNexis US News database 
query for weekly news reports referring to “(avian or 
bird or H5N1) and (ﬂ  u or inﬂ  uenza) and (Tamiﬂ  u or 
oseltamivir).” 
Table 1. Anti-influenza drug prescription rates/100,000 enrollees and proportions of all anti-influenza drug prescriptions, United States, 
weeks 36–44, 2004 and 2005* 
Anti-influenza prescription rates/100,000 enrollees of all ages, weeks 36–44 
% Total anti-influenza 
prescriptions
Medication 2004 2005 Rate ratio (2005/2004)  95% Confidence interval  2004 2005
Neuraminidase inhibitors 
 Oseltamivir  27.3 133 4.88 4.79–4.97 36.99 76.89
 Zanamivir  0.35 1.39 4.00 3.38–4.75 0.47 0.80
Adamantanes
 Amantadine  41.7 36.3 0.87 0.85–0.89 56.53 20.93
 Rimantadine  4.43 2.37 0.54 0.50–0.58 6.00 1.37
All anti-influenza drugs  80.0 173.2 2.17 2.14–2.19 100 100
*Sums do not equal 100% because of rounding. chronic disease category. Although absolute prescription 
rates were lower in persons <50 years of age, persons with-
out chronic medical diagnoses, and children, these groups 
had higher rate increases from 2004 to 2005, suggesting 
that they and their caretakers were inﬂ  uenced to stockpile 
oseltamivir in 2005.
Physician prescribing rates for all specialties increased 
from 2004 toh 2005. Prescription rates in 2004 were high-
est for general internists and family practitioners and likely 
reﬂ  ect the primary care physician’s gatekeeper role as the 
entry point for those seeking medical care. Given the na-
ture of their specialty, infectious diseases physicians may 
be asked to prescribe oseltamivir for personal stockpiles 
more than the typical provider. Because physicians need 
not honor all prescription requests, these increases may not 
be fully explained by increased patient requests because 
physician attitudes regarding personal stockpiling likely 
affected whether requests were made or honored.
Our study is subject to limitations. Although we stud-
ied a large, national population, our study population may 
not be nationally representative. In addition, our analyses 
were limited to prescriptions of oseltamivir that were ﬁ  lled 
by a pharmacy, and we do not know whether prescriptions 
were written with the expressed purpose of personal stock-
piling for use during a pandemic.
In summary, our ﬁ  ndings suggest that increased me-
dia reports during the fall of 2005 about the inﬂ  uenza 
(H5N1) epizootic prompted concern about the possibility 
of an inﬂ  uenza pandemic. This heightened concern led to 
an increase in ﬁ  lled oseltamivir prescriptions for personal 
stockpiling among a national pharmacy beneﬁ  ts member 
population. Subsequently, as inﬂ  uenza virus began circu-
lating in early 2006, oseltamivir prescriptions correspond-
ed more closely with virus activity. Efforts by federal and 
state governments to procure sufﬁ  cient supplies of NIs to 
treat every patient likely to become ill during the next pan-
demic may quell demand in personal stockpiles. Education 
campaigns about appropriate use of antiviral medications 
that target physicians and patients during seasonal epidem-
ics and pandemics may reduce inappropriate requests for 
oseltamivir and other drugs.   
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Table 2. Oseltamivir prescription rates/100,000 enrollees by age and chronic disease classification, United States, weeks 36–44, 2004 
and 2005 
Characteristic 2004 2005 Rate ratio (2005/2004) 95% Confidence  interval
Age group, y 
 <1  0.26 10.65 40.7 (5.6–294) 
 1–4  8.95 65.95 7.4 (6.3–8.6) 
 5–17  11.12 81.28 7.3 (6.8–7.9) 
 18–24  19.55 81.42 4.2 (3.8–4.5) 
 25–49  33.08 120.97 3.7 (3.5–3.8) 
 50–64  63.33 211.26 3.3 (3.2–3.4) 
>65 69.04 168.20 2.4 (2.4–2.5) 
Chronic disease classification* 
 Pulmonary  77.66 268.50 3.46 (3.33–3.60) 
 Immune  deficient  67.75 240.16 3.54 (3.21–3.91) 
 Neurologic  54.57 207.43 3.80 (3.47–4.15) 
 Cardiac  54.11 196.92 3.64 (3.54–3.74) 
 Diabetes  50.85 143.85 2.83 (2.64–3.02) 
  Chronic disease absent  14.07 89.50 6.36 (6.10–6.62) 
*Rates from chronic disease classification include only enrollees >18 y of age only. Except for the chronic disease absent category, all chronic disease 
classifications were not mutually exclusive. Chronic disease classification is derived from the chronic disease index, which has been validated (10). 
Figure 2. Oseltamivir prescription rates/1,000 prescribers by 
specialty, United States, weeks 36–44, 2004 and 2005. Infectious 
diseases classiﬁ   cation includes pediatric and adult infectious 
diseases specialists. All classiﬁ  cations are mutually exclusive. RR, 
rate ratio; CI, conﬁ  dence interval.
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